Alkermes plc (ALKS)

Environment story

Alkermes plc discloses minimal environmental data in available 10-K filings. No Scope 1, 2, or 3 emissions quantification, renewable energy percentage, or net-zero target date are disclosed. The company reports the sale of its Athlone manufacturing facility to Novo in May 2024, reducing direct operational footprint but providing no emissions-reduction detail. Without comprehensive greenhouse-gas accounting, renewable-energy commitments, or decarbonization initiatives, the Environmental score reflects substantial data gaps and inability to verify credible climate action. The company appears to prioritize pharmaceutical product development and manufacturing partnerships over explicit environmental stewardship disclosure.

Social story

Alkermes plc provides no disclosed workforce diversity metrics, CEO-to-median-worker pay ratio, employee turnover rate, or labor-union standing in the 10-K filing. No evidence of documented union suppression, major strikes, or supply-chain human-rights audits is apparent in available sources. The company markets pharmaceutical products (ARISTADA, LYBALVI, VIVITROL) targeting serious mental-health and addiction disorders, suggesting a social-benefit mission aligned with patient welfare. Absence of diversity reporting, executive compensation disclosure, and labor-relations transparency prevents robust social-impact scoring. No supply-chain ethical controversies or plant-safety incidents are disclosed.

Governance story

Alkermes plc discloses no dual-class share structure in available 10-K; share structure assumed single-class with standard voting rights (no deduction applied). Board independence percentage is not disclosed in the filing. No lobbying expenditures targeting environmental deregulation or consumer-protection rollbacks are disclosed. No active antitrust, consumer-safety, or financial-fraud regulatory proceedings are mentioned in the 10-K excerpt. The company engages in Paragraph IV patent-litigation with certain entities regarding LYBALVI (expiration 2041) and VIVITROL (expiration 2029, generic entry expected 2027), representing typical biopharmaceutical IP defense but not material governance violations. Absence of disclosed lobbying, major regulatory penalties, and standard share structure support a mid-range governance score; full board-independence and executive-compensation transparency would strengthen governance assessment.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Alkermes plc. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Alkermes plc in the app for interactive charts and portfolio building.

More in Healthcare